Literature DB >> 8913373

A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.

M Minami1, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata, M Satoh.   

Abstract

Previously, we found that replacement of the region around the first extracellular loop of the delta-opioid receptor (OPR) with the corresponding region of the mu-OPR gives the high affinity for [D-Ala2,N-MePhe4,Gly-ol5]enkephalin (DAMGO), a mu-opioid-selective ligand, to the resultant chimeric receptor, DMDD, suggesting that the difference in the amino acid sequence within this region between the mu- and delta-OPRs is critical for the discrimination between these receptors by DAMGO. In the current study, we carried out systematic replacements of seven non-conserved residues in this region of the delta-OPR with the corresponding amino acid found in the mu-OPR. Among the seven mutant receptors, only one mutant receptor, delta K108N, showed high affinity (Ki = 18.68 +/- 5.27 nM) for DAMGO, which was comparable to that of the DMDD receptor (Ki = 23.77 +/- 4.27 nM) and 75-fold higher than that of the wild-type delta-OPR (Ki = 1405 +/- 161 nM). Lys108 in the delta-OPR was systematically replaced with 19 kinds of amino acids other than lysine. Among the resultant mutant receptors, 14 mutants bound DAMGO with Ki values comparable to those of the DMDD receptor, ranging from 4.20 to 43.38 nM. These findings suggest that Lys108 of the delta-OPR prevents DAMGO from binding to the delta-OPR rather than that the asparagine residue at the corresponding position in the mu-OPR is necessary for DAMGO binding. In addition, the replacement of Lys108 of the delta-OPR with asparagine dramatically increased the affinity for other peptidic mu receptor-selective ligands, such as dermorphin and D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913373

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

2.  Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.

Authors:  A F Marmolejo-Valencia; K Martínez-Mayorga
Journal:  J Comput Aided Mol Des       Date:  2017-03-31       Impact factor: 3.686

3.  The role of the hydrophilic Asn230 residue of the mu-opioid receptor in the potency of various opioid agonists.

Authors:  J Pil; J Tytgat
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

4.  Modulation of the Interaction between a Peptide Ligand and a G Protein-Coupled Receptor by Halogen Atoms.

Authors:  Mònica Rosa; Gianluigi Caltabiano; Katy Barreto-Valer; Verónica Gonzalez-Nunez; José C Gómez-Tamayo; Ana Ardá; Jesús Jiménez-Barbero; Leonardo Pardo; Raquel E Rodríguez; Gemma Arsequell; Gregorio Valencia
Journal:  ACS Med Chem Lett       Date:  2015-07-16       Impact factor: 4.345

5.  A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.

Authors:  Chris M Brasel; Gregory W Sawyer; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2008-10-09       Impact factor: 4.432

6.  Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.

Authors:  I D Pogozheva; A L Lomize; H I Mosberg
Journal:  Biophys J       Date:  1998-08       Impact factor: 4.033

Review 7.  Generic GPCR residue numbers - aligning topology maps while minding the gaps.

Authors:  Vignir Isberg; Chris de Graaf; Andrea Bortolato; Vadim Cherezov; Vsevolod Katritch; Fiona H Marshall; Stefan Mordalski; Jean-Philippe Pin; Raymond C Stevens; Gerrit Vriend; David E Gloriam
Journal:  Trends Pharmacol Sci       Date:  2014-12-22       Impact factor: 14.819

Review 8.  Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors.

Authors:  Yazan J Meqbil; Richard M van Rijn
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.